Full Press Release Details
Biogen Idec and Abbott Announce Enrollment of First Patient in Global Phase III Study of Daclizumab for Relapsing-Remitting Multiple Sclerosis.
BIIB
Biogen Idec and Abbott Announce Enrollment of First Patient in Global Phase III Study of Daclizumab for Relapsing-Remitting Multiple Sclerosis
Key Takeaway: Biogen Idec and Abbott Announce Enrollment of First Patient in Global Phase III Study of Daclizumab for Relapsing-Remitting Multiple Sclerosis